• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Warfarin - Articles and news items

Daiichi Sankyo logo

Phase 3 data show Daiichi Sankyo’s once-daily edoxaban lowered incidence of VTE recurrence and clinically relevant bleeding

Industry news, News / 10 December 2013 / Daiichi Sankyo Company

This analysis of VTE patients with cancer was presented at the 2013 American Society of Hematology Annual Meeting and Exposition…

Daiichi Sankyo logo

Daiichi Sankyo’s once-daily edoxaban meets primary efficacy endpoint for stroke prevention and superiority for the principal safety endpoint compared to Warfarin for patients with atrial fibrillation in a phase 3 clinical trial

Industry news / 20 November 2013 / Daiichi Sankyo Europe

Once-daily edoxaban, evaluated in two treatment arms achieved the primary endpoint of non-inferior efficacy versus warfarin in the prevention of stroke or systemic embolism…

Boehringer Ingelheim logo

Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa® compared to warfarin

Industry news / 7 October 2013 / Boehringer Ingelheim

Post-hoc analysis demonstrates better survival prognosis following a major bleeding with Pradaxa® than with warfarin…

Daiichi Sankyo logo
Boehringer Ingelheim logo
Boehringer Ingelheim logo

AF patients who require surgery benefit from a shorter treatment interruption on dabigatran etexilate (Pradaxa®) compared to warfarin

Industry news, News / 18 June 2012 / Boehringer Ingelheim

Pradaxa® is associated with a substantially shorter interruption of oral anticoagulation therapy…

Boehringer Ingelheim logo

FDA affirms superiority of Pradaxa® (dabigatran etexilate) 150mg over warfarin in reduction of both ischaemic and haemorrhagic strokes

Industry news, News / 6 June 2012 / Boehringer Ingelheim

Boehringer Ingelheim has updated the US prescribing information for Pradaxa®…

Bristol Myers Squibb logo

ELIQUIS® (apixaban) superior to Warfarin for the reduction of stroke or systemic embolism

Industry news, News / 28 August 2011 / Bristol-Myers Squibb Company, Pfizer

Significantly less major bleeding in patients with Atrial Fibrillation in Phase 3 ARISTOTLE trial…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +